Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of SD-101 cream versus placebo in pediatric epidermolysis bullosa
MOH_2026-06-28_016904Phase 3Not yet recruiting
- Sponsor
- Takeda
- Start
- Jun 2026
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in epidermolysis bullosa (EB) comparing SD-101 treatment arm with Placebo arm (2 arms). Primary endpoint: Primary endpoint not reported. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
nelitolimod
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on MOH_2026-06-28_016904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-06-28_016904.